Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Duality Biologics, BioNTech Expand ADC Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Duality Biologics, BioNTech Expand ADC Alliance

To develop, manufacture and commercialize a third ADC candidate DB-1305 globally.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Duality Biologics (Suzhou) Co. Ltd., a clinical-stage biotech company focused on next generation antibody-drug conjugate therapeutics to treat cancer and autoimmune diseases, has expanded  its collaboration with BioNTech SE to develop, manufacture and commercialize a third ADC candidate DB-1305 globally, excluding Mainland China, Hong Kong and Macau Special Administrative Regions. DB-1305 is currently in a Phase 1/2 clinical trial (NCT05438329) for solid tumors. 
 
Under the agreements, DualityBio will receive upfront payments, additional development, regulatory and commercial milestones, and royalties on sales of DB-1305. BioNTech will hold commercial rights globally (excluding Mainland China, Hong Kong and Macau Special Administrative Regions), where DualityBio will retain commercial rights.
 
DB-1305, a third generation Trop2 ADC molecule built from DualityBio’s Duality Immune Toxin Antibody Conjugates (DITAC) platform, exhibited potent antitumor activity in preclinical tumor models and robust clinical efficacy in NSCLC and other solid tumors.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics